A Phase 4 interventional study of Rosiglitazone and Metformin in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 42 sites in 8 countries. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-04-18.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.
Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2008, is one of 21 in phase 4, and was the 47th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 55 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 149 across the 51 interventional studies. Of the 50 that completed or were terminated, 15 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 52 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 133 finished, 46 (35%) have results posted.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 41st largest by enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2008, is one of 23 in phase 4, and was the 63rd registered.
GlaxoSmithKline’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 136 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rosiglitazone up to 8mg/day
Drug: Rosiglitazone
metformin up to 2000mg/day
Drug: Metformin
up to 8mg/day
up to 2000mg/day
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm.
Time frame: Baseline and Week 52
Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline and Week 76+10 days
Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52+10 days and Week 76+10 days
Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline and Week 52
Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+10 Days to Week 76 + 10 Days
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 + 10 days and Week 76 + 10 days
Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+30 Days to Week 76 + 30 Days
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 + 30 days and Week 76 + 30 days
Adjusted Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) at Week 52 and Week 76
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline, Week 52, and Week 76
Adjusted Percent Change in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) From Week 52 to Week 76
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 and Week 76
Adjusted Percent Change From Baseline in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) at Week 52 and Week 76
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline, Week 52, and Week 76
Adjusted Percent Change in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) From Week 52 to Week 76
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 and Week 76
Adjusted Percent Change From Baseline in 25-Hydroxyvitamin D (Vitamin D) at Week 52 and Week 76
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline, Week 52, and Week 76
Adjusted Percent Change in 25-Hydroxyvitamin D (Vitamin D) From Week 52 to Week 76
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 and Week 76
Adjusted Percent Change From Baseline in Intact Parathyroid Hormone (PTH) at Week 52 and Week 76
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Baseline, Week 52, and Week 76
Adjusted Percent Change in Intact Parathyroid Hormone (PTH) From Week 52 to Week 76
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
Time frame: Week 52 and Week 76
Percent Change From Baseline in Serum Estradiol at Week 52 and Week 76
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
Time frame: Baseline, Week 52, and Week 76
Percent Change in Serum Estradiol From Week 52 to Week 76
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
Time frame: Week 52 and Week 76
Percent Change From Baseline in Total Testosterone at Week 52 and Week 76
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
Time frame: Baseline, Week 52, and Week 76
Percent Change in Total Testosterone From Week 52 to Week 76
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
Time frame: Week 52 and Week 76
Percent Change From Baseline in Free Testosterone at Week 52 and Week 76
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
Time frame: Baseline, Week 52, and Week 76
Percent Change in Free Testosterone From Week 52 to Week 76
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
Time frame: Week 52 and Week 76
Percent Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Week 52 and Week 76
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
Time frame: Baseline, Week 52, and Week 76
Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
Time frame: Week 52 and Week 76
Percent Change in Percentage of Free Estradiol From Week 52 to Week 76
Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data.
Time frame: Week 52 and Week 76
Percent Change in Free Estradiol From Week 52 to Week 76
Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data.
Time frame: Week 52 and Week 76
| Milestone | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Started | 114 | 112 |
| Completed | 77 | 85 |
| Not completed | 37 | 27 |
| Withdrew: Withdrew consent | 17 | 13 |
| Withdrew: Adverse event | 14 | 12 |
| Withdrew: Investigator discretion | 5 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Milestone | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Started | 76 | 84 |
| Completed | 69 | 80 |
| Not completed | 7 | 4 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Met stopping criteria | 3 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period |
|---|---|
| Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52 | -1.24 ± 0.619 |
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days | -1.91 ± 0.624 | 0.31 ± 0.636 |
FN BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days | -0.07 ± 0.589 | -0.02 ± 0.585 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Femoral neck, n=52, 54 | -1.24 ± 0.619 | 0.72 ± 0.659 |
| Total hip, n=52, 54 | -0.77 ± 0.417 | -0.38 ± 0.440 |
| Trochanter, n=52, 54 | -0.21 ± 0.725 | -0.78 ± 0.768 |
| Lumbar spine, n=51, 53 | -1.21 ± 0.473 | 0.12 ± 0.505 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Femoral neck, n=56, 62 | -0.07 ± 0.589 | -0.02 ± 0.585 |
| Total hip, n=56, 62 | 0.40 ± 0.304 | -0.13 ± 0.301 |
| Trochanter, n=56, 62 | -0.02 ± 0.475 | -0.68 ± 0.469 |
| Lumbar spine, n=55, 62 | 0.26 ± 0.440 | 1.03 ± 0.442 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Femoral neck, n=64, 73 | -0.27 ± 0.559 | -0.25 ± 0.535 |
| Total hip, n=64, 73 | 0.00 ± 0.298 | -0.27 ± 0.283 |
| Trochanter, n=64, 73 | -0.17 ± 0.495 | -0.47 ± 0.470 |
| Lumbar spine, n=65, 70 | 0.54 ± 0.445 | 0.90 ± 0.442 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone | Metformin |
|---|---|---|
| Week 52, GM - SE, BSAP, n=78, 84 | -15.2 | -29.7 |
| Week 52, GM, BSAP, n=78, 84 | -12.3 | -27.3 |
| Week 52, GM + SE, BSAP, n=78, 84 | -9.3 | -24.8 |
| Week 76, GM - SE, BSAP, n=64, 77 | -18.7 | -26.7 |
| Week 76, GM, BSAP, n=64, 77 | -15.9 | -24.3 |
| Week 76, GM + SE, BSAP, n=64, 77 | -12.9 | -21.8 |
| Week 52, GM - SE, P1NP, n=76, 83 | 5.0 | -16.5 |
| Week 52, GM, P1NP, n=76, 83 | 9.0 | -13.3 |
| Week 52, GM + SE, P1NP, n=76, 83 | 13.3 | -9.9 |
| Week 76 GM - SE, P1NP, n=63, 75 | -11.2 | -14.5 |
| Week 76, GM, P1NP, n=63, 75 | -6.9 | -10.5 |
| Week 76, GM + SE, P1NP, n=63, 75 | -2.4 | -6.4 |
BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE, BSAP, n=64, 76 | -5.6 | 4.3 |
| GM, BSAP, n=64, 76 | -2.0 | 8.0 |
| GM + SE, BSAP, n=64, 76 | 1.8 | 11.8 |
| GM - SE, P1NP, n=63, 76 | -15.8 | 3.2 |
| GM, P1NP, n=63, 76 | -12.4 | 7.0 |
| GM + SE, P1NP, n=63, 76 | -9.0 | 11.0 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=77, 84 | 11.3 | -7.8 |
| Week 52, GM, n=77, 84 | 18.1 | -2.3 |
| Week 52, GM + SE, n=77, 84 | 25.4 | 3.7 |
| Week 76, GM - SE, n=63, 77 | -19.5 | -4.5 |
| Week 76, GM, n=63, 77 | -13.1 | 2.6 |
| Week 76, GM + SE, n=63, 77 | -6.1 | 10.3 |
CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -31.2 | 2.2 |
| GM | -26.7 | 8.4 |
| GM + SE | -21.9 | 14.9 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=61, 65 | -27.9 | -15.9 |
| Week 52, GM, n=61, 65 | -24.7 | -12.2 |
| Week 52, GM + SE, n=61, 65 | -21.4 | -8.4 |
| Week 76, GM - SE, n=55, 58 | -21.3 | -12.5 |
| Week 76, GM, n=55, 58 | -18.1 | -8.9 |
| Week 76, GM + SE, n=55, 58 | -14.6 | -5.2 |
Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -4.7 | -7.7 |
| GM | 0.1 | -3.2 |
| GM + SE | 5.1 | 1.5 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=64, 71 | -16.5 | -25.9 |
| Week 52, GM, n=64, 71 | -12.0 | -22.0 |
| Week 52, GM + SE, n=64, 71 | -7.2 | -17.8 |
| Week 76, GM - SE, n=56, 64 | -28.8 | -26.2 |
| Week 76, GM, n=56, 64 | -23.1 | -20.8 |
| Week 76, GM + SE, n=56, 64 | -17.0 | -15.0 |
Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -13.2 | -1.7 |
| GM | -7.4 | 4.3 |
| GM + SE | -1.3 | 10.7 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=74, 82 | -17.0838 | -31.4166 |
| Week 52, GM, n=74, 82 | -3.453 | -17.280 |
| Weel 52, GM + SE, n=74, 82 | 12.4189 | -0.2292 |
| Week 76, GM - SE, n=64, 76 | -16.0971 | 0.4372 |
| Week 76, GM, n=64, 76 | 0.215 | 21.389 |
| Week 76, GM + SE, n=64, 76 | 19.6987 | 46.7122 |
Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -15.2056 | 29.3058 |
| GM | 0.513 | 50.823 |
| GM + SE | 19.1447 | 75.9217 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=74, 82 | 14.1569 | -5.8206 |
| Week 52, GM, n=74, 82 | 19.689 | 1.044 |
| Week 52, GM + SE, n=74, 82 | 25.4897 | 8.4082 |
| Week 76, GM - SE, n=64, 75 | -12.5441 | -8.2870 |
| Week 76, GM, n=64, 75 | -8.156 | -2.932 |
| Week 76, GM + SE, n=64, 75 | -3.5470 | 2.7363 |
Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -29.0307 | -13.9923 |
| GM | -24.373 | -7.102 |
| GM + SE | -19.4104 | 0.3411 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=74, 82 | -9.9964 | 2.5725 |
| Week 52, GM, n=74, 82 | -5.940 | 6.266 |
| Week 52, GM + SE, n=74, 82 | 1.7006 | 10.0934 |
| Week 76, GM - SE, n=64, 75 | -0.3232 | -1.9532 |
| Week 76, GM, n=64, 75 | 3.687 | 2.478 |
| Week 76, GM + SE, n=64, 75 | 7.8593 | 7.1093 |
Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | 3.1109 | -6.9549 |
| GM | 8.993 | -3.537 |
| GM + SE | 15.2100 | 0.0073 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, GM - SE, n=74, 83 | 33.2608 | 4.3929 |
| Week 52, GM, n=74, 83 | 37.563 | 8.146 |
| Week 52, GM + SE, n=74, 83 | 42.0049 | 12.0349 |
| Week 76, GM - SE, n=61, 67 | -0.2973 | 4.0983 |
| Week 76, GM, n=61, 67 | 3.137 | 9.846 |
| Week 76, GM + SE, n=61, 67 | 6.6896 | 15.9116 |
SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -27.0129 | -3.9036 |
| GM | -24.624 | -0.825 |
| GM + SE | -22.1566 | 2.3517 |
Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -7.6337 | -5.4666 |
| GM | -2.683 | -0.975 |
| GM + SE | 2.5337 | 3.7301 |
Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| GM - SE | -29.5250 | 96.1843 |
| GM | -3.239 | 173.932 |
| GM + SE | 32.8525 | 282.4903 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 + 10 days or Week 76 + 10 days was calculated as (BMD at Week 52 + 10 days (or Week 76 + 10 days ) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 10 days; Femoral neck (FN), n=70, 78 | -1.47 ± 0.521 | 0.22 ± 0.512 |
| Week 52 + 10 days; Total hip (TH), n=70, 78 | -1.62 ± 0.386 | -0.72 ± 0.379 |
| Week 52 + 10 days; Trochanter (Tro.), n=70, 78 | -1.45 ± 0.602 | -1.04 ± 0.589 |
| Week 52 + 10 days; Lumbar spine (LS), n=70, 76 | -1.41 ± 0.416 | 0.04 ± 0.419 |
| Week 76 + 10 days; FN, n=65, 70 | -1.91 ± 0.624 | 0.31 ± 0.636 |
| Week 76 + 10 days; TH, n=65, 70 | -1.70 ± 0.415 | -0.83 ± 0.420 |
| Week 76 + 10 days; Tro., n=65, 70 | -2.14 ± 0.644 | -1.35 ± 0.650 |
| Week 76 + 10 days; LS, n=65, 71 | -1.24 ± 0.452 | 0.85 ± 0.457 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by DXA. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (BMD at Week 52 + 30 days (or Week 76 + 30 days) minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days; Femoral neck (FN), n=77, 83 | -1.59 ± 0.503 | 0.24 ± 0.498 |
| Week 52 + 30 days; Total hip (TH), n=77, 83 | -1.79 ± 0.370 | -0.72 ± 0.364 |
| Week 52 + 30 days; Trochanter (Tro.), n=77, 83 | -1.83 ± 0.583 | -1.01 ± 0.574 |
| Week 52 + 30 days; Lumbar spine (LS), n=79, 81 | -1.60 ± 0.417 | 0.11 ± 0.421 |
| Week 76 + 30 days; FN, n=66, 74 | -2.05 ± 0.620 | 0.29 ± 0.619 |
| Week 76 + 30 days; TH, n=66, 74 | -1.79 ± 0.408 | -0.68 ± 0.404 |
| Week 76 + 30 days; Tro., n=66, 74 | -2.53 ± 0.508 | -0.96 ± 0.575 |
| Week 76 + 30 days; LS, n=66, 72 | -1.15 ± 0.464 | 1.13 ± 0.467 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (BMD at Week 52 + 30 days (orWeek 76 + 30 days) minus BMD at baseline)/BMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days; Femoral neck (FN), n=32, 35 | -2.39 ± 0.895 | 0.09 ± 0.986 |
| Week 52 + 30 days; Total hip (TH), n=32, 35 | -3.39 ± 0.475 | 0.09 ± 0.521 |
| Week 52 + 30 days; Trochanter (Tro.), n=32, 35 | -4.53 ± 0.612 | -0.23 ± 0.669 |
| Week 52+30 days; Intertrochanter (Inter.),n=32, 35 | -3.36 ± 0.515 | 0.77 ± 0.565 |
| Week 76+30 days; Femoral neck (FN), n=31, 30 | -1.98 ± 0.587 | -1.52 ± 0.705 |
| Week 76 + 30 days; TH, n=31, 30 | -2.11 ± 0.495 | -0.32 ± 0.591 |
| Week 76 + 30 days; Tro., n=31, 30 | -2.86 ± 0.752 | -1.28 ± 0.892 |
| Week 76 + 30 days; Inter., n=31, 30 | -1.66 ± 0.525 | 0.30 ± 0.627 |
BMD (measured in grams per centimeters squared \[g/cm\^2\]) was measured by QCT. BMD by QCT is the 2-dimensional volume that mimics the DXA measurement for the same region. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| percent change | 0.95 ± 0.728 | -1.39 ± 0.866 |
| Total hip | 1.61 ± 0.346 | -0.18 ± 0.411 |
| Trochanter | 1.81 ± 0.534 | -0.91 ± 0.632 |
| Intertrochanter | 2.05 ± 0.428 | -0.25 ± 0.507 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Baseline was calculated as (vBMD at Week 52+30 days (or Week 76+30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days; Integral, n=32, 35 | -3.60 ± 0.587 | 0.99 ± 0.645 |
| Week 52 + 30 days; Trabecular, n=32, 35 | -3.63 ± 1.243 | 0.21 ± 1.376 |
| Week 52 + 30 days; Cortical, n=32, 35 | -0.54 ± 0.537 | 0.52 ± 0.603 |
| Week 76 + 30 days; Integral, n=31, 30 | -1.70 ± 0.657 | 0.85 ± 0.786 |
| Week 76 + 30 days; Trabecular, n=31, 30 | -2.66 ± 1.211 | 0.70 ± 1.445 |
| Week 76 + 30 days; Cortical, n=31, 30 | 0.23 ± 0.421 | 0.50 ± 0.518 |
Volumetric (v)BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. vBMD is the 3-dimensional density of a region of bone. Cortical bone is dense bone. Trabecular bone is spongy bone. Integral bone is the sum of cortical and trabecular bone measurements. Cortical thickness is the width of the cortical shell. Percent change from Week 52 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/ vBMD at Week 52 + 30 days x 100% and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 2.24 ± 0.483 | -0.20 ± 0.5746 |
| Trabecular | 0.90 ± 1.252 | 1.15 ± 1.491 |
| Cortical | 0.94 ± 0.449 | -0.06 ± 0.548 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -3.72 ± 1.097 | 0.58 ± 1.208 |
| Week 52 + 30 days, Trabecular, n=32, 35 | -1.83 ± 1.695 | 0.91 ± 1.867 |
| Week 52 + 30 days, Cortical, n=32, 35 | -1.00 ± 0.735 | -0.20 ± 0.819 |
| Week 76 + 30 days, Integral, n=31, 30 | -2.13 ± 0.946 | -0.61 ± 1.141 |
| Week 76 + 30 days, Trabecular, n=31, 30 | -1.05 ± 1.798 | 2.27 ± 2.141 |
| Week 76 + 30 days, Cortical, n=31, 30 | -0.46 ± 0.599 | -1.60 ± 0.723 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 2.21 ± 0.871 | -1.37 ± 1.040 |
| Trabecular | 0.27 ± 1.721 | 2.21 ± 2.044 |
| Cortical | 1.03 ± 0.774 | -1.30 ± 0.929 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -4.80 ± 0.666 | 0.01 ± 0.730 |
| Week 52 + 30 days, Trabecular, n=32, 35 | -3.43 ± 1.157 | 0.67 ± 1.275 |
| Week 52 + 30 days, Cortical, n=32, 35 | -1.26 ± 0.490 | -0.18 ± 0.540 |
| Week 76 + 30 days, Integral, n=31, 30 | -2.88 ± 0.748 | -0.93 ± 0.889 |
| Week 76 + 30 days, Trabecular, n=31, 30 | -2.42 ± 1.085 | 0.92 ± 1.293 |
| Week 76 + 30 days, Cortical, n=31, 30 | -0.49 ± 0.384 | -0.64 ± 0.462 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| percent change | 2.22 ± 0.506 | -0.90 ± 0.600 |
| Trabecular | 1.07 ± 1.138 | 0.95 ± 1.353 |
| Cortical | 0.78 ± 0.396 | -0.65 ± 0.474 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -3.47 ± 0.621 | 2.18 ± 0.683 |
| Week 52 + 30 days, Trabecular, n=32, 35 | -4.26 ± 1.341 | -0.22 ± 1.485 |
| Week 52 + 30 days, Cortical, n=32, 35 | -0.76 ± 0.568 | 0.99 ± 0.631 |
| Week 76 + 30 days, Integral, n=31, 30 | -0.92 ± 0.746 | 1.88 ± 0.895 |
| Week 76 + 30 days, Trabecular, n=31, 30 | -3.09 ± 1.278 | 0.27 ± 1.525 |
| Week 76 + 30 days, Cortical, n=31, 30 | 0.41 ± 0.472 | 0.79 ± 0.573 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| percent change | 2.83 ± 0.563 | -0.46 ± 0.671 |
| Trabecular | 1.16 ± 1.298 | 1.21 ± 1.545 |
| Cortical | 1.29 ± 0.479 | -0.27 ± 0.577 |
BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | -6.71 ± 1.454 | -1.72 ± 1.601 |
| Week 76 + 30 days, n=31, 30 | -5.15 ± 1.121 | -3.91 ± 1.337 |
BMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Vertebral Trabecular vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days | 3.53 ± 1.454 | -2.11 ± 1.727 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days orWeek 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -10.26 ± 2.194 | -0.03 ± 2.417 |
| Week 52 + 30 days, Trabecular, n=32, 35 | 2.77 ± 5.848 | 5.57 ± 6.420 |
| Week 52 + 30 days, Cortical, n=32, 35 | -3.76 ± 0.836 | -0.66 ± 0.922 |
| Week 76 + 30 days, Integral, n=31, 30 | -4.21 ± 2.094 | 1.07 ± 2.508 |
| Week 76 + 30 days, Trabecular, n=31, 30 | 2.37 ± 7.040 | 10.24 ± 8.362 |
| Week 76 + 30 days, Cortical, n=31, 30 | -1.65 ± 0.730 | -1.30 ± 0.877 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-posterior is the upper and back section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior and Cortical vBMD Via QCT at Week 76 + 30 Days | -8.007 ± 3.4199 | -7.006 ± 4.1114 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 8.29 ± 3.262 | 0.52 ± 3.884 |
| Trabecular | 36.05 ± 31.815 | -11.69 ± 37.721 |
| Cortical | 2.17 ± 0.944 | -0.94 ± 1.129 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therpay, and region. Supero-posterior is the upper and back section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 9.30 ± 4.287 | -4.92 ± 5.130 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | -20.48 ± 3.614 | 1.00 ± 3.986 |
| Week 76 + 30 days, n=31,30 | -3.52 ± 3.674 | -1.50 ± 4.423 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days | -0.95 ± 0.0537 | -0.067 ± 0.0647 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days | 32.42 ± 10.358 | -7.80 ± 2.383 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Supero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 0.18 ± 0.049 | -0.05 ± 0.059 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 daysor Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days(or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -6.56 ± 2.106 | -0.58 ± 2.311 |
| Week 52 + 30 days, Trabecular, n=32, 35 | 3.59 ± 4.719 | 2.82 ± 5.180 |
| Week 52 + 30 days, Cortical, n=32, 35 | -1.91 ± 0.901 | -0.25 ± 0.977 |
| Week 76 + 30 days, Integral, n=31, 30 | -4.97 ± 2.384 | -2.45 ± 2.838 |
| Week 76 + 30 days, Trabecular, n=31, 30 | -0.85 ± 6.050 | 3.98 ± 7.171 |
| Week 76 + 30 days, Cortical, n=31, 30 | -0.93 ± 0.745 | -1.49 ± 0.876 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days | -4.555 ± 3.5006 | -7.553 ± 4.1177 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 2.96 ± 2.202 | -1.81 ± 2.609 |
| Trabecular | -2.78 ± 4.677 | 6.63 ± 5.531 |
| Cortical | 1.19 ± 0.778 | -1.28 ± 0.912 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Supero-anterior is the upper and front section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical vBMD Via QCT From Week 52+30 Days to Week 76 + 30 Days | 5.19 ± 3.686 | -6.24 ± 4.319 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days(or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | -13.45 ± 5.002 | 5.05 ± 5.453 |
| Week 76 + 30 days, n=31, 30 | -4.23 ± 4.491 | -4.78 ± 5.327 |
Cortical thickness was measured by QCT. Change from baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days | -0.117 ± 0.0484 | -0.087 ± 0.0575 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 14.02 ± 6.779 | -13.65 ± 7.995 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Supero-anterior Cortical Thickness Via QCT From Week 52+30 Days to Week 76 + 30 Days | 0.11 ± 0.052 | -0.13 ± 0.061 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (or Week 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -4.11 ± 1.074 | 1.74 ± 1.200 |
| Week 52 + 30 days, Trabecular, n=32, 35 | -84.08 ± 270.700 | 282.16 ± 297.445 |
| Week 52 + 30 days, Cortical, n=32, 35 | -3.42 ± 1.531 | 1.14 ± 1.694 |
| Week 76 + 30 days, Integral, n=31, 30 | -3.11 ± 0.933 | 0.01 ± 1.147 |
| Week 76 + 30 days, Trabecular, n=31, 30 | 24.46 ± 17.473 | 13.54 ± 20.790 |
| Week 76 + 30 days, Cortical, n=31, 30 | -1.32 ± 1.234 | -1.17 ± 1.492 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT at Week 76 + 30 Days | -12.424 ± 8.9945 | -10.244 ± 10.8703 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 1.47 ± 1.183 | -1.87 ± 1.435 |
| Trabecular | -39.81 ± 130.071 | 161.81 ± 154.179 |
| Cortical | 2.67 ± 1.728 | -2.50 ± 2.076 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-posterior is the lower and back section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 15.48 ± 11.544 | -17.59 ± 13.865 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (or Week 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | 0.47 ± 1.977 | -1.27 ± 2.180 |
| Week 76 + 30 days, n=31, 30 | -1.46 ± 1.593 | -0.11 ± 1.910 |
Cortical thickness was measured by QCT. Change from Baseline was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT at Week 76 + 30 Days | -0.082 ± 0.0816 | -0.048 ± 0.0978 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | -1.48 ± 1.552 | 2.04 ± 1.846 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Infero-posterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | -0.08 ± 0.078 | 0.07 ± 0.093 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Baseline at Week 52 + 30 days or Week 76 + 30 days was calculated as (vBMD at Week 52 + 30 days (orWeek 76 + 30 days) minus vBMD at baseline)/vBMD at Baseline x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, Integral, n=32, 35 | -4.35 ± 1.950 | 1.26 ± 2.163 |
| Week 52, Trabecular, n=32, 35 | -161.59 ± 774.589 | 930.71 ± 851.727 |
| Week 52, Cortical, n=32, 35 | -1.85 ± 1.309 | 0.85 ± 1.563 |
| Week 76 + 30 days, Integral, n=31, 30 | -0.29 ± 2.301 | 0.54 ± 2.810 |
| Week 76 + 30 days, Trabecular, n=31, 30 | 81.29 ± 35.959 | 37.81 ± 42.791 |
| Week 76 + 30 days, Cortical, n=31, 30 | 1.45 ± 1.149 | -0.63 ± 1.409 |
vBMD was measured by QCT. Change from Baseline at Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at baseline and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT at Week 76 + 30 Days | 7.901 ± 6.9912 | -5.025 ± 8.5722 |
vBMD (measured in milligrams per centimeters cubed \[mg/cm\^3\]) was measured by QCT. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days)/vBMD at Week 52 + 30 days x 100% and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Integral | 5.05 ± 1.878 | 0.38 ± 2.268 |
| Trabecular | -90.60 ± 167.792 | 260.13 ± 199.323 |
| Cortical | 3.68 ± 1.649 | -1.64 ± 2.016 |
vBMD was measured by QCT. Change from Week 52 + 30 days to Week 76 + 30 days was calculated as vBMD at Week 76 + 30 days minus vBMD at Week 52 + 30 days and was assessed by an analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Infero-anterior is the lower and front section of the FN.
| mg/cm^3 | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical vBMD Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 20.15 ± 9.677 | -10.73 ± 11.830 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 52 + 30 days (orWeek 76 + 30 days) minus thickness at Baseline)/thickness at Baseline x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52 + 30 days, n=32, 35 | -6.05 ± 2.393 | 0.64 ± 2.656 |
| Week 76 + 30 days, n=31, 30 | -3.59 ± 2.804 | 0.39 ± 3.421 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Baseline.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change From Baseline in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT at Week 76 + 30 Days | -0.120 ± 0.0931 | -0.040 ± 0.1135 |
Cortical thickness (measured in millimeters) was measured by QCT. Percent change was calculated as (thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days)/thickness at Week 52 + 30 days x 100%.
| percent change | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Percent Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 3.12 ± 2.127 | 1.56 ± 2.257 |
Cortical thickness was measured by QCT. Change was calculated as thickness at Week 76 + 30 days minus thickness at Week 52 + 30 days.
| millimeters | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Femoral Neck (FN) Infero-anterior Cortical Thickness Via QCT From Week 52 + 30 Days to Week 76 + 30 Days | 0.09 ± 0.065 | 0.01 ± 0.078 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from baseline was calculated as the Week 52or Week 76 value minus the baseline value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| millimoles per Liter (mmol/L) | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Week 52, n=73, 83 | 0.01 ± 0.009 | 0.03 ± 0.009 |
| Week 76, n=64, 75 | 0.03 ± 0.010 | 0.04 ± 0.010 |
AASC levels were measured from blood samples. AASC is the amount of free calcium circulating in the blood and calcium is required for good bone health. Change from Week 52 was calculated as the Week 76 value minus the Week 52 value and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
| millimoles per Liter (mmol/L) | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period |
|---|---|---|
| Adjusted Change in Albumin-adjusted Serum Calcium (AASC) From Week 52 to Week 76 | 0.01 ± 0.011 | 0.00 ± 0.010 |
Collected over 76 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosiglitazone: DB | — | 7/114 (6.1%) | 47/115 (40.9%) |
| Metformin: DB | — | 5/111 (4.5%) | 45/111 (40.5%) |
| Rosiglitazone: MET OL | — | 0/76 (0%) | 12/76 (15.8%) |
| Metformin: MET OL | — | 0/84 (0%) | 8/84 (9.5%) |
| Event | Rosiglitazone: DB | Metformin: DB | Rosiglitazone: MET OL | Metformin: MET OL |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 1/114 | 1/111 | 0/76 | 0/84 |
| Enteritis infectiousInfections and infestations | 0/114 | 1/111 | 0/76 | 0/84 |
| Cerebral infarctionNervous system disorders | 0/114 | 1/111 | 0/76 | 0/84 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/114 | 1/111 | 0/76 | 0/84 |
| Coronary artery diseaseCardiac disorders | 0/114 | 1/111 | 0/76 | 0/84 |
| Wrist fractureInjury, poisoning and procedural complications | 0/114 | 1/111 | 0/76 | 0/84 |
| Alanine aminotransferase increasedInvestigations | 0/114 | 1/111 | 0/76 | 0/84 |
| Device dislocationGeneral disorders | 1/114 | 0/111 | 0/76 | 0/84 |
| Generalised oedemaGeneral disorders | 1/114 | 0/111 | 0/76 | 0/84 |
| Sudden cardiac deathGeneral disorders | 1/114 | 0/111 | 0/76 | 0/84 |
| Event | Rosiglitazone: DB | Metformin: DB | Rosiglitazone: MET OL | Metformin: MET OL |
|---|---|---|---|---|
| Oedemal peripheralGeneral disorders | 17/115 | 0/111 | 0/76 | 0/84 |
| DiarrhoeaGastrointestinal disorders | 3/115 | 15/111 | 6/76 | 1/84 |
| HeadacheNervous system disorders | 9/115 | 5/111 | 1/76 | 1/84 |
| Weight increasedInvestigations | 9/115 | 1/111 | 0/76 | 0/84 |
| NasopharyngitisInfections and infestations | 7/115 | 7/111 | 1/76 | 0/84 |
| NauseaGastrointestinal disorders | 3/115 | 3/111 | 3/76 | 5/84 |
| DyspepsiaGastrointestinal disorders | 2/115 | 6/111 | 0/76 | 0/84 |
| InfluenzaInfections and infestations | 3/115 | 6/111 | 0/76 | 1/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/115 | 6/111 | 1/76 | 0/84 |
| FatigueGeneral disorders | 6/115 | 4/111 | 0/76 | 0/84 |
| Age, Continuous(Years) | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period | Total |
|---|---|---|---|
| Mean | 63.6 ± 6.61 | 64.0 ± 6.46 | 63.8 ± 6.52 |
| Sex: Female, Male(Participants) | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period | Total |
|---|---|---|---|
| Female | 114 | 111 | 225 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Rosiglitazone in DB Period; Metformin in OL Period | Metformin in DB Period; Metformin in OL Period | Total |
|---|---|---|---|
| White - White/Caucasian/European | 82 | 78 | 160 |
| African American/African | 2 | 8 | 10 |
| American Indian or Alaskan Native | 6 | 5 | 11 |
| Asian - Central/South Asian | 13 | 10 | 23 |
| South East Asian | 4 | 6 | 10 |
| Mixed Race | 3 | 2 | 5 |
| East Asia | 4 | 2 | 6 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosiglitazone · Metformin